NCT04771390View on ClinicalTrials.gov

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

May 20, 2021

Study Completion Date

July 6, 2021

Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
DRUG

Selitrectinib (BAY2731954) Adult tablet

Tablet, oral administration

DRUG

Selitrectinib (BAY2731954) Pediatric tablet

Tablet, oral administration

DRUG

Selitrectinib (BAY2731954) Oral solution

Oral solution after reconstitution

DRUG

Selitrectinib (BAY2731954) Oral suspension

Oral suspension after reconstitution

Trial Locations (2)

21225

PAREXEL International, Baltimore, Baltimore

91206

Parexel International - Los Angeles, Glendale

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04771390 - Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants | Biotech Hunter | Biotech Hunter